Wechselwirkungen von Salmeterol

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Excessive Use of SEREVENT DISKUS and Use with Other Long-acting Beta 2 -agonists SEREVENT DISKUS should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (Fachinformation zu Dronabinol, Warnhinweise und Vorsichtsmaßnahmen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

Excessive Use of SEREVENT DISKUS and Use with Other Long-acting Beta 2 -agonists SEREVENT DISKUS should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines. (Fachinformation zu Imipramin, Arzneimittelwechselwirkungen)

In the SNS trial, the rate of asthma-related death was numerically, though not statistically significantly, greater in subjects with asthma treated with salmeterol (42 mcg twice daily) than those treated with albuterol (180 mcg 4 times daily) added to usual asthma therapy. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Known Hypersensitivity or Idiosyncrasy to the Sympathomimetic Amines NUMBRINO is contraindicated in patients with a known history of hypersensitivity to cocaine or to the components of the nasal solution. (Fachinformation zu Kokain, Warnhinweise und Vorsichtsmaßnahmen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Excessive Use of SEREVENT DISKUS and Use with Other Long-acting Beta 2 -agonists SEREVENT DISKUS should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (Fachinformation zu Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

The potentiation of sympathomimetic substances and related compounds by MAO inhibitors may result in hypertensive crises (see WARNINGS ). (Fachinformation zu Phenelzin, Gegenanzeigen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

IF INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND REINSTITUTED ONLY WITH EXTREME CAUTION, CONTINUOUS MONITORING AND CONSIDERATION OF CONCOMITANT ADMINISTRATION OF BRONCHODILATORS (SEE WARNINGS ). (Fachinformation zu Ribavirin, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (Fachinformation zu Roflumilast, Warnhinweise und Vorsichtsmaßnahmen)

In the SNS trial, the rate of asthma-related death was numerically, though not statistically significantly, greater in subjects with asthma treated with salmeterol (42 mcg twice daily) than those treated with albuterol (180 mcg 4 times daily) added to usual asthma therapy. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Excessive Use of SEREVENT DISKUS and Use with Other Long-acting Beta 2 -agonists SEREVENT DISKUS should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

…(SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) tricyclic antidepressants other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine. (Fachinformation zu Tranylcypromin, Boxed Warning (umrahmter Warnhinweis))

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

Excessive Use of SEREVENT DISKUS and Use with Other Long-acting Beta 2 -agonists SEREVENT DISKUS should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (Fachinformation zu Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (Fachinformation zu Aclidiniumbromid, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (Fachinformation zu Alogliptin und Metformin, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Albuterol (or other beta 2 agonists): Increase the frequency of monitoring blood pressure and heart rate. (Fachinformation zu Atomoxetin, Arzneimittelwechselwirkungen)

Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Fachinformation zu Bortezomib, Warnhinweise und Vorsichtsmaßnahmen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (Fachinformation zu Dicycloverin, Arzneimittelwechselwirkungen)

Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (Fachinformation zu Digoxin, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (Fachinformation zu Doxapram, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

…somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

…olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

…Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin aspart, Arzneimittelwechselwirkungen)

…Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin degludec, Arzneimittelwechselwirkungen)

…Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin detemir, Arzneimittelwechselwirkungen)

…Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin glargin, Arzneimittelwechselwirkungen)

…Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin lispro, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (Fachinformation zu Ketamin, Warnhinweise und Vorsichtsmaßnahmen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Sympathomimetics Concurrent use may of sympathomimetics and levothyroxine may increase the effects of sympathomimetics or thyroid hormone. (Fachinformation zu Levothyroxin, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Interrupt MARGENZA infusion in patients experiencing dyspnea or clinically significant hypotension and intervene with medical therapy which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators and oxygen. (Fachinformation zu Margetuximab, Warnhinweise und Vorsichtsmaßnahmen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (Fachinformation zu Nateglinid, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

…somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Beta-blockers: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (Fachinformation zu Tiotropiumbromid, Arzneimittelwechselwirkungen)

Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (Fachinformation zu Tolcapon, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (Fachinformation zu Zanamivir, Warnhinweise und Vorsichtsmaßnahmen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (Fachinformation zu Acarbose, Arzneimittelwechselwirkungen)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (Fachinformation zu Bevacizumab, Warnhinweise und Vorsichtsmaßnahmen)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (Fachinformation zu Bromocriptin, Arzneimittelwechselwirkungen)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Dapagliflozin und Metformin, Arzneimittelwechselwirkungen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Empagliflozin und Metformin, Arzneimittelwechselwirkungen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Glibenclamid und Metformin, Arzneimittelwechselwirkungen)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5/17) and 0% (0/13) of patients with and without a diagnosis of asthma, respectively. (Fachinformation zu Humaninsulin (Normalinsulin), Warnhinweise und Vorsichtsmaßnahmen)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (Fachinformation zu Ipratropiumbromid, Warnhinweise und Vorsichtsmaßnahmen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Linagliptin und Metformin, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Metformin, Arzneimittelwechselwirkungen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Pioglitazon und Metformin, Arzneimittelwechselwirkungen)

…antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (Fachinformation zu Rituximab, Warnhinweise und Vorsichtsmaßnahmen)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Saxagliptin und Metformin, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Sitagliptin und Metformin, Arzneimittelwechselwirkungen)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (Fachinformation zu Tobramycin, Arzneimittelwechselwirkungen)

Acute symptoms should be treated with an inhaled, short-acting beta 2 -agonist. (Fachinformation zu Umeclidiniumbromid, Warnhinweise und Vorsichtsmaßnahmen)